PharmaMar collaboration activities with the following patients associations

2016

More information about the collaborations

Know more

2015

More information about the collaborations

Know more

2014

More information about the collaborations

Know more

Oncology pipeline

PharmaMar develops and commercializes YONDELIS® in Europe and has three clinical-stage drug candidates under development for several types of solid and hematological cancers, Aplidin ®, Lurbinectedin, and PM184.

Shareholders and Investors

Financial Information of the Company, stock information, official notices to the CNMV (Spanish Securities & Exchange Commission), product portfolio and other information.

Newsroom

If you need information about the company, our clinical trials, corporate images or multimedia, visit our newsroom